Comprehensive tobacco treatment can help cancer patients quit and abstain from smoking, according to a study from MD Anderson Cancer Center.
Lynparza (olaparib) demonstrated statistically significant and clinically meaningful improvement in the primary endpoint of radiographic progression-free survival in certain tumors.
Older patients with breast cancer who exercised before diagnosis may be at a lower risk for cardiovascular disease compared to those who did not, according to a study in JACC: CardioOncology.
Roughly one in five young adults uses e-cigarettes daily or recreationally, and nearly one in four believes the products are harmless and not addictive, according to findings from the American Society of Clinical Oncology third annual National Cancer Opinion Survey.
A research team at the University of Arizona College of Medicine are developing potent and selective T-type calcium channel antagonists as potential novel pain medicines to treat chemotherapy-induced peripheral neuropathy.
Providers with more experience treating people with multiple myeloma have better outcomes than those with more limited experience, according to a study in the September issue of the Journal of the National Comprehensive Cancer Network.
A phase III study on CC-486 as maintenance therapy in patients with newly diagnosed acute myeloid leukemia found statistically significant and clinically meaningful improvement in overall survival compared to placebo.
The randomized phase II GRIFFIN study showing that the addition of Darzalex (daratumumab) to bortezomib, lenalidomide, and dexamethasone induced higher response rates in newly diagnosed patients with multiple myeloma who were eligible for high-dose therapy and autologous stem cell transplantation compared with VRd alone.
A new clinical pathway for patients at Christiana Care's Helen F. Graham Cancer Center & Research Institute improves quality of life, provides better health outcomes, and delivers lower health care costs, according to a study published in the Journal of Clinical Pathways.
Two independent studies show that OVA1 (Blood Multivariate Index Assay (MIA) for Ovarian Cancer Risk Assessment) improves ovarian cancer risk detection in women compared to alternative technology, according to Vermillion, a bioanalytical-based women's health company focused on gynecologic disease.
